272P Primary prevention of bone fractures in patients (pts) with hormone receptor (HR)+ early breast cancer (EBC) during adjuvant hormonal therapy (HT): The predict & prevent project (P&P)
Stefania Gori(Ospedale Sacro Cuore Don Calabria), Fabrizio Nicolis(Ospedale Sacro Cuore Don Calabria), Michela Verzè(Ospedale Sacro Cuore Don Calabria), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Saverio Cinieri(Ospedale A. Perrino), Fabio Puglisi(University of Udine), Tiziana Prochilo(Fondazione Poliambulanza Istituto Ospedaliero), Rossana Berardi(Marche Polytechnic University), Claudia Bighin(Azienda Ospedaliera S.Maria), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Alessandra Fabi(Agostino Gemelli University Polyclinic), Mario Airoldi, A. Orlandi(Agostino Gemelli University Polyclinic), Alessandro Del Conte(University of Catania), Alessandra Chirco(Ospedale Papa Giovanni XXIII), Laura Orlando, Matteo Valerio(Ospedale Sacro Cuore Don Calabria)
Cited by 0
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751